Biodexa Pharmaceuticals (BDRX) Cash & Equivalents (2013 - 2025)

Biodexa Pharmaceuticals has reported Cash & Equivalents for 13 years, with the latest figure at $11.4 million in Q4 2025.

• Quarterly Cash & Equivalents rose 429.91% year-over-year to $11.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.4 million (up 429.91% YoY) and the FY2025 annual result came in at $11.3 million, up 425.27% from the prior year.
• Cash & Equivalents improved to $11.4 million in Q4 2025 per BDRX's latest filing, from $5.4 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $13.6 million in Q4 2021 and troughed at $2.1 million in Q4 2024.
• A 5-year average of $7.0 million and a median of $6.5 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents sank 75.46% in 2022, then surged 429.91% in 2025.
• Over 5 years, Cash & Equivalents stood at $13.6 million in 2021, then slumped by 75.46% to $3.3 million in 2022, then jumped by 122.79% to $7.4 million in 2023, then sank by 71.09% to $2.1 million in 2024, then soared by 429.91% to $11.4 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $11.4 million, $5.4 million, and $2.1 million for Q4 2025, Q2 2025, and Q4 2024 respectively.